Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 123

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 123
---
 candidate, called JOTROL, has many potential indications of use for rare diseases.
We are primarily targeting Parkinson’s Disease. In addition, and more broadly, JOTROL has potential indications for use related
to the rare diseases Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS as well as the larger Mild Cognitive Impairment/early
Alzheimer’s disease.

JOTROL
has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream, using a unique patented micellar formulation,
without causing gastrointestinal side effects. Based on the results of the Company’s Phase I study, JOTROL may resolve the major
obstacle of resveratrol’s poor bioavailability, which has been documented in various scientific articles describing previously
conducted human trials with resveratrol as well as preclinical trial results in mice and rats.

The
Company’s Phase 1 dose finding pharmacokinetics (“PK”) study was completed in 2021 and funded by the U.S. National
Institute on Aging, an institute of the U.S. National Institutes of Health (“NIH”): Safety and Pharmacokinetics of
JOTROL for Alzheimer’s Disease, Federal Award Identification Number R44AG067907-01A1 (the “Award”). This Phase 1
PK study will be homogeneous for all indications where JOTROL will be used in Phase II and Phase III clinical trials.

Initial
Public Offering

In
December 2024, the Company’s sold 2,750,000 shares of Common Stock at a price of $4.00 per share for gross proceeds of $11 million before underwriting discounts and other related expenses in a registered
initial public offering (the “IPO”). Net proceeds, after deducting underwriting discounts, commissions, and offering-related
expenses, were approximately $9,725,213. In connection with the Public Offering, the Company’s Common Stock began trading on The
Nasdaq Capital Market under the symbol “JUNS.”

Nasdaq
Minimum Bid Price Compliance

On
March 21, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the
Company was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), which requires listed securities
to maintain a minimum closing bid price of $1.00 per share for at least 30